Accepted at 9:57 p.m. Sep, 22, 2023 by herstein.jacob
Author: GG
Related Note: 1488850186903
Rationale for change

ideallly < 90, should not exceed 120
Source: AMBOSS - https://www.amboss.com/us/knowledge/Acute_coronary_syndrome/

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy



Watch Thrombolytics
Sketchy 2


Watch STEMI Management
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize



Watch Thrombolytics (tPA, Streptokinase, Urokinase)
Physeo

Bootcamp
Watch associated Bootcamp video - Myocardial Infarction: Management

Watch associated Bootcamp video - Fibrinolysis and Inhibitors of Hemostasis
OME

Additional Resources
One by one
Empty field
#AK_Step1_v12::#Bootcamp::Cardiology::24_Myocardial_Infarction::06_Management #PANCE::EOR::Family_med #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::06_Thrombolytics #AK_Step1_v12::#B&B::11_Hematology::01_Hemostasis::07_Anticoagulants #AK_Step2_v12::#AMBOSS::890O6R #AK_Step2_v12::#OME::01_Medicine::01_Cardiology::02_Acute_Coronary_Syndrome #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::05_Thrombolytics_(tPA/Streptokinase/Urokinase) #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::04_Thrombolytics #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::04_Fibrinolysis_and_Inhibitors_of_Hemostasis #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step2_v12::#AMBOSS::9w0NOR #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::04_Thrombolytics #AK_Step1_v12::#B&B::05_Cardio::02_Ischemia::03_ST-Elevation_Myocardial_Infarction_(STEMI) #AK_Step2_v12::#SketchyIM::01_Cardiology::01_Ischemic_Heart_Disease::07_STEMI_Management !AK_UpdateTags::Step1decks::Zanki-Pharmacology